Annual CFI
-$105.78 M
-$195.72 M-217.61%
31 December 2023
Summary:
Celldex Therapeutics annual cash flow from investing activities is currently -$105.78 million, with the most recent change of -$195.72 million (-217.61%) on 31 December 2023. During the last 3 years, it has fallen by -$7.56 million (-7.70%). CLDX annual CFI is now -217.61% below its all-time high of $89.94 million, reached on 31 December 2022.CLDX Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
$47.76 M
+$94.48 M+202.22%
01 September 2024
Summary:
Celldex Therapeutics quarterly cash flow from investing activities is currently $47.76 million, with the most recent change of +$94.48 million (+202.22%) on 01 September 2024. Over the past year, it has increased by +$36.11 million (+310.08%). CLDX quarterly CFI is now -9.15% below its all-time high of $52.57 million, reached on 31 March 2023.CLDX Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
-$485.34 M
+$36.11 M+6.93%
01 September 2024
Summary:
Celldex Therapeutics TTM cash flow from investing activities is currently -$485.34 million, with the most recent change of +$36.11 million (+6.93%) on 01 September 2024. Over the past year, it has dropped by -$581.93 million (-602.46%). CLDX TTM CFI is now -467.32% below its all-time high of $132.13 million, reached on 31 March 2023.CLDX TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CLDX Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -217.6% | +310.1% | -602.5% |
| 3 y3 years | -7.7% | +121.1% | -191.7% |
| 5 y5 years | -454.8% | +765.3% | -2921.1% |
CLDX Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -217.6% | +51.1% | -9.2% | +115.2% | -467.3% | +6.9% |
| 5 y | 5 years | -217.6% | +51.1% | -9.2% | +115.2% | -467.3% | +6.9% |
| alltime | all time | -217.6% | +51.1% | -9.2% | +115.2% | -467.3% | +6.9% |
Celldex Therapeutics Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $47.76 M(-202.2%) | -$485.34 M(-6.9%) |
| June 2024 | - | -$46.72 M(-85.2%) | -$521.45 M(+10.1%) |
| Mar 2024 | - | -$315.21 M(+84.2%) | -$473.56 M(+347.7%) |
| Dec 2023 | -$105.78 M(-217.6%) | -$171.16 M(-1569.7%) | -$105.78 M(-209.5%) |
| Sept 2023 | - | $11.65 M(+900.5%) | $96.59 M(-10.6%) |
| June 2023 | - | $1.16 M(-97.8%) | $108.01 M(-18.3%) |
| Mar 2023 | - | $52.57 M(+68.4%) | $132.13 M(+46.9%) |
| Dec 2022 | $89.94 M(-141.6%) | $31.21 M(+35.3%) | $89.94 M(+126.1%) |
| Sept 2022 | - | $23.07 M(-8.8%) | $39.78 M(-118.9%) |
| June 2022 | - | $25.28 M(+143.6%) | -$210.07 M(-15.7%) |
| Mar 2022 | - | $10.38 M(-154.8%) | -$249.26 M(+15.3%) |
| Dec 2021 | -$216.16 M(+120.1%) | -$18.94 M(-91.6%) | -$216.16 M(+29.9%) |
| Sept 2021 | - | -$226.79 M(+1530.2%) | -$166.36 M(-1028.3%) |
| June 2021 | - | -$13.91 M(-132.0%) | $17.92 M(-123.4%) |
| Mar 2021 | - | $43.49 M(+41.0%) | -$76.70 M(-21.9%) |
| Dec 2020 | -$98.22 M(-675.0%) | $30.85 M(-172.6%) | -$98.22 M(-22.0%) |
| Sept 2020 | - | -$42.51 M(-60.8%) | -$125.85 M(+61.7%) |
| June 2020 | - | -$108.53 M(-594.1%) | -$77.82 M(-442.1%) |
| Mar 2020 | - | $21.96 M(+581.3%) | $22.75 M(+33.2%) |
| Dec 2019 | $17.08 M(-42.7%) | $3.22 M(-41.6%) | $17.08 M(-0.7%) |
| Sept 2019 | - | $5.52 M(-169.3%) | $17.20 M(+81.8%) |
| June 2019 | - | -$7.96 M(-148.8%) | $9.46 M(-69.1%) |
| Mar 2019 | - | $16.30 M(+386.7%) | $30.62 M(+2.7%) |
| Dec 2018 | $29.82 M(-35.8%) | $3.35 M(-250.7%) | $29.82 M(+127.8%) |
| Sept 2018 | - | -$2.22 M(-116.8%) | $13.09 M(-22.9%) |
| June 2018 | - | $13.19 M(-14.8%) | $16.97 M(-57.1%) |
| Mar 2018 | - | $15.49 M(-215.8%) | $39.56 M(-14.9%) |
| Dec 2017 | $46.47 M(-32.6%) | -$13.38 M(-903.7%) | $46.47 M(-47.0%) |
| Sept 2017 | - | $1.67 M(-95.3%) | $87.63 M(-13.1%) |
| June 2017 | - | $35.78 M(+59.7%) | $100.89 M(+53.4%) |
| Mar 2017 | - | $22.40 M(-19.4%) | $65.77 M(-4.6%) |
| Dec 2016 | $68.91 M(-237.3%) | $27.78 M(+86.2%) | $68.91 M(+15.1%) |
| Sept 2016 | - | $14.92 M(+2136.6%) | $59.87 M(+4.6%) |
| June 2016 | - | $667.00 K(-97.4%) | $57.21 M(+41.7%) |
| Mar 2016 | - | $25.54 M(+36.3%) | $40.38 M(-180.5%) |
| Dec 2015 | -$50.19 M(+22.4%) | $18.74 M(+52.9%) | -$50.19 M(-2.0%) |
| Sept 2015 | - | $12.26 M(-175.9%) | -$51.24 M(+12.7%) |
| June 2015 | - | -$16.16 M(-75.1%) | -$45.48 M(+84.0%) |
| Mar 2015 | - | -$65.03 M(-467.5%) | -$24.72 M(-39.7%) |
| Dec 2014 | -$41.01 M(-47.0%) | $17.70 M(-1.8%) | -$41.01 M(-43.5%) |
| Sept 2014 | - | $18.02 M(+291.8%) | -$72.53 M(-14.7%) |
| June 2014 | - | $4.60 M(-105.7%) | -$84.99 M(-24.2%) |
| Mar 2014 | - | -$81.33 M(+488.4%) | -$112.17 M(+44.9%) |
| Dec 2013 | -$77.42 M(+356.0%) | -$13.82 M(-348.7%) | -$77.42 M(+13.6%) |
| Sept 2013 | - | $5.56 M(-124.6%) | -$68.14 M(+0.6%) |
| June 2013 | - | -$22.58 M(-51.5%) | -$67.71 M(+87.8%) |
| Mar 2013 | - | -$46.58 M(+926.6%) | -$36.05 M(+112.3%) |
| Dec 2012 | -$16.98 M(+687.9%) | -$4.54 M(-175.8%) | -$16.98 M(+286.0%) |
| Sept 2012 | - | $5.99 M(-34.0%) | -$4.40 M(>+9900.0%) |
| June 2012 | - | $9.08 M(-133.0%) | -$34.00 K(-99.9%) |
| Mar 2012 | - | -$27.51 M(-442.0%) | -$34.93 M(+1521.0%) |
| Dec 2011 | -$2.15 M(-86.7%) | $8.04 M(-22.3%) | -$2.15 M(-19.8%) |
| Sept 2011 | - | $10.35 M(-140.1%) | -$2.69 M(-75.5%) |
| June 2011 | - | -$25.82 M(-590.0%) | -$10.96 M(+226.6%) |
| Mar 2011 | - | $5.27 M(-29.8%) | -$3.36 M(-79.2%) |
| Dec 2010 | -$16.16 M(-135.8%) | $7.51 M(+261.5%) | -$16.16 M(-176.9%) |
| Sept 2010 | - | $2.08 M(-111.4%) | $21.01 M(+11.7%) |
| June 2010 | - | -$18.22 M(+141.7%) | $18.81 M(-48.9%) |
| Mar 2010 | - | -$7.54 M(-116.9%) | $36.84 M(-18.3%) |
| Dec 2009 | $45.09 M(+344.0%) | $44.68 M(<-9900.0%) | $45.09 M(+7358.0%) |
| Sept 2009 | - | -$115.00 K(-37.8%) | $604.60 K(+515.1%) |
| June 2009 | - | -$185.00 K(-126.1%) | $98.30 K(-23.0%) |
| Mar 2009 | - | $710.00 K(+264.9%) | $127.60 K(-98.7%) |
| Dec 2008 | $10.15 M(-2556.5%) | $194.60 K(-131.3%) | $10.15 M(+5.5%) |
| Sept 2008 | - | -$621.30 K(+299.0%) | $9.62 M(-32.8%) |
| June 2008 | - | -$155.70 K(-101.5%) | $14.32 M(+37.9%) |
| Mar 2008 | - | $10.74 M(-3274.8%) | $10.38 M(-2611.5%) |
| Dec 2007 | -$413.40 K | -$338.20 K(-108.3%) | -$413.40 K(-112.5%) |
| Sept 2007 | - | $4.08 M(-199.6%) | $3.31 M(-190.7%) |
| June 2007 | - | -$4.09 M(+6897.4%) | -$3.65 M(+136.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2007 | - | -$58.50 K(-101.7%) | -$1.54 M(-28.9%) |
| Dec 2006 | -$2.17 M(-0.3%) | $3.38 M(-217.6%) | -$2.17 M(-66.0%) |
| Sept 2006 | - | -$2.88 M(+44.7%) | -$6.37 M(+58.0%) |
| June 2006 | - | -$1.99 M(+190.5%) | -$4.03 M(+61.4%) |
| Mar 2006 | - | -$684.40 K(-16.9%) | -$2.50 M(+15.0%) |
| Dec 2005 | -$2.17 M(+31.2%) | -$823.50 K(+53.3%) | -$2.17 M(+51.1%) |
| Sept 2005 | - | -$537.30 K(+18.3%) | -$1.44 M(-30.4%) |
| June 2005 | - | -$454.20 K(+26.6%) | -$2.07 M(+16.8%) |
| Mar 2005 | - | -$358.70 K(+304.4%) | -$1.77 M(+6.9%) |
| Dec 2004 | -$1.66 M(-192.6%) | -$88.70 K(-92.4%) | -$1.66 M(-165.4%) |
| Sept 2004 | - | -$1.17 M(+644.7%) | $2.53 M(-30.7%) |
| June 2004 | - | -$156.70 K(-35.9%) | $3.65 M(-1.4%) |
| Mar 2004 | - | -$244.30 K(-106.0%) | $3.71 M(+107.0%) |
| Dec 2003 | $1.79 M(-312.9%) | $4.10 M(-8843.1%) | $1.79 M(-170.6%) |
| Sept 2003 | - | -$46.90 K(-54.6%) | -$2.53 M(-4.1%) |
| June 2003 | - | -$103.40 K(-95.2%) | -$2.64 M(-4.3%) |
| Mar 2003 | - | -$2.16 M(+869.2%) | -$2.76 M(+228.7%) |
| Dec 2002 | -$840.60 K(+8.4%) | -$222.90 K(+42.4%) | -$840.60 K(+4.2%) |
| Sept 2002 | - | -$156.50 K(-30.0%) | -$807.00 K(-12.9%) |
| June 2002 | - | -$223.50 K(-6.0%) | -$926.10 K(+0.3%) |
| Mar 2002 | - | -$237.70 K(+25.6%) | -$923.50 K(+19.1%) |
| Dec 2001 | -$775.40 K(-19.7%) | -$189.30 K(-31.3%) | -$775.40 K(-45.2%) |
| Sept 2001 | - | -$275.60 K(+24.8%) | -$1.41 M(+12.2%) |
| June 2001 | - | -$220.90 K(+146.5%) | -$1.26 M(+9.3%) |
| Mar 2001 | - | -$89.60 K(-89.2%) | -$1.15 M(+19.4%) |
| Dec 2000 | -$966.20 K(-129.6%) | -$828.20 K(+577.2%) | -$966.20 K(-17.4%) |
| Sept 2000 | - | -$122.30 K(+7.3%) | -$1.17 M(+11.7%) |
| June 2000 | - | -$114.00 K(-216.0%) | -$1.05 M(+1.4%) |
| Mar 2000 | - | $98.30 K(-109.5%) | -$1.03 M(-131.6%) |
| Dec 1999 | $3.27 M(-57.0%) | -$1.03 M(<-9900.0%) | $3.27 M(-54.0%) |
| Sept 1999 | - | $0.00(-100.0%) | $7.10 M(-43.2%) |
| June 1999 | - | -$100.00 K(-102.3%) | $12.50 M(+3.3%) |
| Mar 1999 | - | $4.40 M(+57.1%) | $12.10 M(+59.2%) |
| Dec 1998 | $7.60 M(+406.7%) | $2.80 M(-48.1%) | $7.60 M(+61.7%) |
| Sept 1998 | - | $5.40 M(-1180.0%) | $4.70 M(-687.5%) |
| June 1998 | - | -$500.00 K(+400.0%) | -$800.00 K(+166.7%) |
| Mar 1998 | - | -$100.00 K(0.0%) | -$300.00 K(-120.0%) |
| Dec 1997 | $1.50 M(-850.0%) | -$100.00 K(0.0%) | $1.50 M(-11.8%) |
| Sept 1997 | - | -$100.00 K(<-9900.0%) | $1.70 M(-10.5%) |
| June 1997 | - | $0.00(-100.0%) | $1.90 M(+11.8%) |
| Mar 1997 | - | $1.70 M(+1600.0%) | $1.70 M(-950.0%) |
| Dec 1996 | -$200.00 K(-103.4%) | $100.00 K(0.0%) | -$200.00 K(-87.5%) |
| Sept 1996 | - | $100.00 K(-150.0%) | -$1.60 M(-42.9%) |
| June 1996 | - | -$200.00 K(0.0%) | -$2.80 M(+3.7%) |
| Mar 1996 | - | -$200.00 K(-84.6%) | -$2.70 M(-145.8%) |
| Dec 1995 | $5.90 M(-49.1%) | -$1.30 M(+18.2%) | $5.90 M(-72.0%) |
| Sept 1995 | - | -$1.10 M(+1000.0%) | $21.10 M(-4.1%) |
| June 1995 | - | -$100.00 K(-101.2%) | $22.00 M(+5.3%) |
| Mar 1995 | - | $8.40 M(-39.6%) | $20.90 M(+80.2%) |
| Dec 1994 | $11.60 M(-1.7%) | $13.90 M(-7050.0%) | $11.60 M(+11.5%) |
| Sept 1994 | - | -$200.00 K(-83.3%) | $10.40 M(+1.0%) |
| June 1994 | - | -$1.20 M(+33.3%) | $10.30 M(-8.0%) |
| Mar 1994 | - | -$900.00 K(-107.1%) | $11.20 M(-5.1%) |
| Dec 1993 | $11.80 M(-427.8%) | $12.70 M(-4333.3%) | $11.80 M(-1411.1%) |
| Sept 1993 | - | -$300.00 K(0.0%) | -$900.00 K(-10.0%) |
| June 1993 | - | -$300.00 K(0.0%) | -$1.00 M(0.0%) |
| Mar 1993 | - | -$300.00 K(-25.0%) | -$1.00 M(-16.7%) |
| Dec 1992 | -$3.60 M(+414.3%) | - | - |
| Oct 1992 | - | -$400.00 K(+33.3%) | -$1.20 M(+33.3%) |
| July 1992 | - | -$300.00 K(0.0%) | -$900.00 K(+28.6%) |
| Apr 1992 | - | -$300.00 K(+50.0%) | -$700.00 K(+40.0%) |
| Apr 1992 | -$700.00 K(+75.0%) | - | - |
| Jan 1992 | - | -$200.00 K(+100.0%) | -$500.00 K(0.0%) |
| Oct 1991 | - | -$100.00 K(0.0%) | -$500.00 K(+25.0%) |
| July 1991 | - | -$100.00 K(0.0%) | -$400.00 K(0.0%) |
| Apr 1991 | -$400.00 K(-55.6%) | -$100.00 K(-50.0%) | -$400.00 K(+33.3%) |
| Jan 1991 | - | -$200.00 K(<-9900.0%) | -$300.00 K(+200.0%) |
| Oct 1990 | - | $0.00(-100.0%) | -$100.00 K(0.0%) |
| July 1990 | - | -$100.00 K | -$100.00 K |
| Apr 1990 | -$900.00 K | - | - |
FAQ
- What is Celldex Therapeutics annual cash flow from investing activities?
- What is the all time high annual CFI for Celldex Therapeutics?
- What is Celldex Therapeutics annual CFI year-on-year change?
- What is Celldex Therapeutics quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Celldex Therapeutics?
- What is Celldex Therapeutics quarterly CFI year-on-year change?
- What is Celldex Therapeutics TTM cash flow from investing activities?
- What is the all time high TTM CFI for Celldex Therapeutics?
- What is Celldex Therapeutics TTM CFI year-on-year change?
What is Celldex Therapeutics annual cash flow from investing activities?
The current annual CFI of CLDX is -$105.78 M
What is the all time high annual CFI for Celldex Therapeutics?
Celldex Therapeutics all-time high annual cash flow from investing activities is $89.94 M
What is Celldex Therapeutics annual CFI year-on-year change?
Over the past year, CLDX annual cash flow from investing activities has changed by -$195.72 M (-217.61%)
What is Celldex Therapeutics quarterly cash flow from investing activities?
The current quarterly CFI of CLDX is $47.76 M
What is the all time high quarterly CFI for Celldex Therapeutics?
Celldex Therapeutics all-time high quarterly cash flow from investing activities is $52.57 M
What is Celldex Therapeutics quarterly CFI year-on-year change?
Over the past year, CLDX quarterly cash flow from investing activities has changed by +$36.11 M (+310.08%)
What is Celldex Therapeutics TTM cash flow from investing activities?
The current TTM CFI of CLDX is -$485.34 M
What is the all time high TTM CFI for Celldex Therapeutics?
Celldex Therapeutics all-time high TTM cash flow from investing activities is $132.13 M
What is Celldex Therapeutics TTM CFI year-on-year change?
Over the past year, CLDX TTM cash flow from investing activities has changed by -$581.93 M (-602.46%)